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Abstract
Background: Increased survival of extremely low birth infants due to advances in antenatal and neonatal
care has resulted in a population of infants at high risk of developing retinopathy of prematurity (ROP).
Therapeutic interventions include the use of antenatal and postnatal steroids however, their effects on the
severity of ROP is in dispute. In addition, it has not been investigated whether severe ROP is due to
therapeutic interventions or due to the severity of illness. The aim of the present study was to assess the
association between the incidence of severe retinopathy of prematurity (greater than stage 2 –
International classification of ROP) and mechanical ventilation, oxygen therapy, gestational age, antenatal
and postnatal steroids in extremely low birth weight infants.
Methods: Neonates admitted to the neonatal intensive care unit in Lansing, Michigan, during 1993–2000
were followed to determine factors influencing the development of severe retinopathy of prematurity.
Ophthalmologic examinations were started at 6 weeks and followed until resolution. We used logistic
regression to estimate the relative risk (odds ratio) associated with risk factors of ROP.
Results: Of the neonates with ≤  1500 g birth weight, admitted to the neonatal intensive care unit, 85%
(616/725) survived. Severe retinopathy of prematurity was detected in 7.8% of 576 neonates who had eye
examinations. Neonates of lower gestational age (≤  25 weeks and 26–28 weeks) had an increased odds
ratio of 8.49 and 3.19 for the development of severe retinopathy of prematurity, respectively, compared
to those 29 weeks and older. Late postnatal steroid treatment starting after 3 weeks of life showed 2.9-
fold increased odds ratio, in particular administration for two weeks and more (OR: 4.09, 95% CI: 1.52–
11.03). With increasing antenatal steroids courses the risk of severe retinopathy of prematurity decreased,
however, it was not significant. Lower gestational age, dependence on ventilation, and use of postnatal
steroids were intertwined. Simultaneous presence of these factors seems to indicate severe disease status.
Conclusion: Prolonged and late postnatal steroids treatment in very low birth weight infants may pose
an increased risk for the development of severe retinopathy of prematurity; however, use of postnatal
steroids may also be a marker for severity of illness. Further studies need to focus on biologic markers in
the pathogenesis of retinopathy of prematurity and to better understand the influence of therapies.
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Background
Retinopathy of prematurity (ROP) is the main cause of
visual impairment in premature infants [1]. The increased
survival of extremely low birth weight (ELBW) infants in
recent years, due to advances in neonatal care, has pro-
duced a population of infants at very high risk of develop-
ing ROP [2]. It has been believed for many years that
oxygen therapy increases the risk of ROP in preterm
infants [3]. However, ROP can occur even with careful
control of oxygen therapy [4]. Several factors increase the
risk of ROP, especially those associated with short gesta-
tion and low birth weight [5]. Other identified risk factors
include sepsis, intraventricular hemorrhage, exposure to
light [6], and blood transfusions [7], and mechanical ven-
tilation [8].
One of the recent changes in the care of low birth weight
(LBW) infants is administration of antenatal steroids
(ANS) to reduce the risk of respiratory distress syndrome
(RDS) and neonatal death in preterm neonates [9]. The
1994 National Institute of Health consensus development
conference recommended the administration of ANS for
pregnancies 24 to 34 weeks threatened with premature
delivery [10]. Despite strong support for giving a single
course of ANS, the need is far less clear for continuing this
regimen in high-risk women who have not delivered one
week after their initial course. A survey of members of the
Society of Perinatal Obstetricians in 1995 reported that
96% of respondents were willing to give more than one
course of ANS and 58% would give more than six courses
of ANS [11]. In addition, postnatal steroids (PNS) have
been used increasingly for the prevention and treatment
of Chronic Lung Disease (CLD) in LBW infants [12].
However, reports concerning the association between
postnatal dexamethasone (PNS) use and the incidence of
ROP are contradictory [13-16]. Recent Cochrane reviews
concluded no significant effect of early therapy with PNS
on severe ROP, but late PNS use revealed increased risk of
severe ROP (RR = 1.52, 95%CI: 1.09–2.12) [17-19]. How-
ever, the conclusion for late PNS use is based only on 241
children from six studies.
Not only are there controversies around the effect of ante-
natal and postnatal steroids on the incidence and severity
of ROP in ELBW infants, effects of multiple antenatal ster-
oid courses on the incidence and severity of ROP has not
yet been assessed. The primary focus of this study was to
examine the relationship between severe ROP and ANS
courses, late use of postnatal steroids and its duration,
mechanical ventilation, oxygen therapy, and gestational
age.
Methods
Subjects and clinical data
All very low birth weight (VLBW, ≤ 1500 g) neonates, hos-
pitalized in the Neonatal Intensive Care Unit (NICU) at
Sparrow Hospital from January 1993 to July 2000 and
who survived until discharge, were eligible for the study.
Infants with lethal congenital anomalies were excluded.
Data for all patients admitted to the NICU were entered
into a computerized neonatal database (medical data sys-
tems, Pennsylvania). We retrieved and analyzed data for
these patients. Antenatal steroids (Betamethasone) 12
mg, 2 doses at 24-hour intervals were administered prena-
tally to women with threatened preterm labor at 24 – 34
weeks gestation. Gestational age was determined by either
the last menstrual period or ultrasound and confirmed by
neonatal examination. Surfactant was given to infants
who met clinical and radiologic criteria for respiratory dis-
tress syndrome (RDS) as a rescue treatment within 2–6
hours of life. Patent ductus arteriosus was diagnosed by
echocardiography and treated per protocol. Intraventricu-
lar hemorrhage was diagnosed by serial cranial ultrasound
studies. Chronic Lung Disease (CLD) was defined as a
requirement for supplemental oxygen at 36 weeks post-
conceptional age and chest x-ray changes consistent with
CLD. Usually 3–4 weeks after delivery, postnatal dexame-
thasone treatment was initiated at the discretion of the
individual neonatologist for the treatment of CLD, for
high oxygen need, or inability to wean infant from respi-
ratory support. A single pediatric ophthalmologist did all
eye examinations starting at 6 weeks after delivery. Follow
up examinations were done until the resolution of ROP or
retinal maturation and used the international classifica-
tion of ROP to classify the severity [20]. None of the
babies received additional supplementation of Vitamin E.
Statistical analyses
In order to determine whether the incidence of ROP was
increased in specific exposure levels, we grouped continu-
ous variables: gestational age: ≤  25 weeks, 26–28 weeks,
and > 28 weeks; exposure to ANS: no, 0.5, 1, 2, ≥  3
courses; duration of ventilation: no, 1, 2, ≥  3 weeks, expo-
sure to PNS: no, 1, 2, ≥  3 weeks. To assess the relative risk
of PNS in multivariate models, we decided to dichot-
omize post-natal steroids use into any exposure versus no
exposure.
We assessed risk factors for severe ROP (>stage 2). Since
we had twins in the sample and data of twins are corre-
lated, the use of logistic regression would not be justified.
Hence we used Generalized Estimation Equations (SAS,
PROC GENMOD) that allows adjusting for autocorrela-
tion between observations [21]. We estimated odds ratios
(OR) and their 95% confidence intervals (95% CI) for all
potential risk factors. We then reduced the model to the
most parsimonious set of predictors, by eliminating allBMC Pediatrics 2005, 5:18 http://www.biomedcentral.com/1471-2431/5/18
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potential predictors that showed no important associa-
tion (OR not different from 1) and that did not change the
OR of the other predictors by more than 10% when elim-
inated from a full model. All above mentioned procedures
were carried out using SAS software version 8.02 [22].
The study protocol was approved by the human subject
review committee of Michigan State University.
Results
During the observation period from 1993 to 2000, 725
very low birth weight (VLBW) infants were admitted to
the neonatal intensive care unit (NICU). A total of 616
infants (85%) survived until hospital discharge. Eye
examination was performed on 576 infants; 40 infants
(6.5%) were lost to follow up. From 1993 to 2000, the
incidence of severe retinopathy of prematurity (ROP)
changed only slightly in our neonatal intensive care unit
(Figure 1). The use of antenatal steroids showed a major
increase during 1993 – 1994 and a minor change thereaf-
ter. The use of PNS increased during the last four years of
the study. Hence on this aggregative level, there seems to
be no association between severe ROP with antenatal or
postnatal use of steroids.
However, on an individual level the incidence of severe
ROP was associated with postnatal administration of ster-
oids for greater than 1-week duration (Table 1). Beyond
that, there was an obvious increase with gestational age
and a reduced incidence in African American neonates.
The explanatory model for severe ROP, mutually
controlling for all predictors, is provided in Table 2. Com-
pared to Caucasian children, the odds ratio was signifi-
cantly lower in African American children. Gender,
Incidence of severe retinopathy of prematurity (> stage 2 – International classification of ROP) and treatment with prenatal and  postnatal steroids in the neonatal intensive care unit, Lansing, Michigan Figure 1
Incidence of severe retinopathy of prematurity (> stage 2 – International classification of ROP) and treatment with prenatal and 
postnatal steroids in the neonatal intensive care unit, Lansing, Michigan.
0
10
20
30
40
50
60
70
80
90
1993
(n=63)
1994
(n=76)
1995
(n=70)
1996
(n=86)
1997
(n=84)
1998
(n=73)
1999
(n=65)
2000
(n=58)
I
n
c
i
d
e
n
c
e
 
o
f
 
s
e
v
e
r
e
 
R
O
P
 
a
n
d
 
u
s
e
 
o
f
 
s
t
e
r
o
i
d
s
 
(
%
)
Retinopathy of
prematurity
Postnatal steroids
Prenatal SteroidsBMC Pediatrics 2005, 5:18 http://www.biomedcentral.com/1471-2431/5/18
Page 4 of 8
(page number not for citation purposes)
respiratory distress syndrome, oxygen treatment at 36
weeks post-conceptional age, and prenatal use of steroids
were not significantly associated with severe ROP. A more
parsimonious model included only three significant fac-
tors: gestational age, duration of ventilation, and postna-
tal steroids. The incidence of severe ROP clearly decreased
with increasing gestational age (Table 2). Late postnatal
treatment with steroids showed a 2.9-fold increased odds
ratio (95% CI: 1.17–7.28) for the development of severe
ROP. Duration of ventilation was not significant but
needed to be controlled for as it changed the effect of post-
natal steroids and gestational age.
At the onset of the analysis, we dichotomized postnatal
steroid application (none vs. any, Table 2). However,
descriptive data in Table 1 suggested a threshold between
one and two weeks of postnatal steroids used. Thus, we
additionally analyzed a three-category variable. The anal-
yses revealed that, compared to no postnatal steroid
administration, there was no increased relative risk (odds
ratio) for postnatal steroids used for seven days and less,
but an increased risk if used for two weeks and more (OR:
4.09, 95% CI: 1.52–11.03). Additionally, we had infor-
mation on the dose of postnatal steroids for 488 of 576
children. A steroid administration of two weeks or more
corresponded to a dose of ≥  7 mg in 73.7% of the
neonates.
The three factors, gestational age, duration of ventilation,
and late administration of postnatal steroids, were inter-
twined (Figure 2). Among infants who received postnatal
steroids, 65–76% were dependent on ventilation for more
than two weeks, but only 4.4% (13/296) of the infants
older than 28 weeks with ≤  2 weeks of ventilation received
postnatal steroids. We further attempted to test the signif-
icance of combined effects of the three predictors on the
incidence of severe ROP. However, high collinearity
between them averted further statistical assessments. Nev-
ertheless, when comparing the incidence of severe ROP in
different combinations of these three factors, it was nota-
bly higher in infants treated with postnatal steroids (Fig-
ure 3), in particular infants with a low gestational age and
infants dependent on ventilation for more than two
weeks. The majority of cases of severe ROP were in infants
with lower gestational age (<28 weeks). In this group
without the use of postnatal steroids, the incidence of
Table 1: Incidence of Retinopathy of Prematurity (ROP) by patient characteristics.
n No ROP (%) ≤  stage 2 ROP (%) > stage 2 ROP (%)
Total cohort 576 63.4 28.8 7.8
Gender boys 308 64.6 27.0 8.4
girls 268 61.9 31.0 7.1
Gestational age ≤  25 weeks 61 4.9 59.0 36.1
26–28 weeks 198 42.9 47.0 10.1
> 28 weeks 317 87.4 11.7 1.0
Race White 433 62.8 27.7 9.5
Black 109 68.8 18.7 2.8
Other 34 52.9 44.1 2.9
Use of antenatal 
steroids
no 153 60.1 31.4 8.5
0.5 course 83 59.0 28.9 12.1
1 course 236 66.1 27.5 6.4
2 courses 51 62.8 25.5 11.8
≥  3 courses 53 67.9 30.2 1.9
Respiratory distress 
syndrome
no 293 78.5 18.1 3.4
yes 283 47.7 39.9 12.4
Ventilator no 200 87 12.5 0.5
1 week 174 82.8 15.5 1.7
>1 – 2 weeks 48 54.2 39.6 6.3
>2 weeks 154 13.6 61.7 24.7
Use of postnatal 
steroids
no 422 78.7 19.2 2.1
1 week 47 37.2 61.7 2.1
> 1 – 2 weeks 38 15.8 52.6 31.6
> 2 weeks 62 6.5 21.7 48.9
Oxygen for 36 weeks no 474 70.9 23.3 4.9
yes 102 28.4 50.0 21.6BMC Pediatrics 2005, 5:18 http://www.biomedcentral.com/1471-2431/5/18
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severe ROP increased from 3% (3/100) to 15.2% (5/33);
and in the group with postnatal steroids from 20% (4/20)
to 28.8% (30/104) with varying duration of ventilation.
Discussion
Our study was comprised of 576 neonates with ≤  1500 g
birth weights, of which 7.8% developed severe ROP
(greater than stage 2 – International classification of
ROP). Gestational age, duration of ventilation, and late
postnatal steroids administration were significantly asso-
ciated with severity of ROP. Gestational age and duration
on ventilation were associated with development of ROP
[8,23]. Consistent with published data, incidence of
severe ROP was higher in Caucasians than African Ameri-
can infants [24,25].
Antenatal steroid use has been recommended for preg-
nancies 24 to 34 weeks gestation with threatened prema-
ture delivery to decrease the risk of RDS and neonatal
death in premature neonates. ANS (dexamethasone) has
been reported to be associated with decreased incidence
of severe ROP [26]. However, Smith et al. have reported
that single or multiple courses of ANS were not protective
for the development of severe ROP [27,28]. In our study
neither single nor multiple courses of ANS imparted a sig-
nificant difference for the incidence of severe ROP.
In retrospective studies, postnatal steroid administration
has been shown to either have a protective effect on the
incidence of severity of ROP (case-control study with 58
newborns) [13], no effect (retrospective review with 147
newborns) [15], or on the contrary, increases the severity
of ROP and need for cryotherapy (case control study with
52 newborns) [14].
Meta-analyses of prospective, randomized, placebo-con-
trolled trials found no effect on the incidence of severe
ROP when postnatal steroids were used early (within 96
hours after birth, eight studies, 1,453 infants) or within 7–
14 days of life (five studies, 247 infants) for treatment of
CLD [18,19]. However, a significant increase in severe
ROP was reported when PNS was used after 3 weeks of life
to treat CLD among 241 VLBW infants in six randomized
placebo controlled trials (late administration) [17]. This is
Table 2: Odds ratio for risk factors of Retinopathy of Prematurity (ROP).
Full Model Reduced Model
n = 570 n = 570
Odds-Ratio 95% CI Odds-Ratio 95% CI
Gestational age >28 weeks >28 weeks 1 - 1
26–28 weeks 4.12 1.05–16.11 3.19 0.81–12.55
≤  25 weeks 11.27 2.61–48.66 8.49 2.0–35.94
Race Caucasian 1 -
Other 0.22 0.03–2.0
African American 0.18 0.05–0.68
Gender Boys 1 -
Girls 0.71 0.33–1.52
Antenatal steroids No 1 -
0.5 course 0.78 0.27–2.28
1 course 0.50 0.17–1.26
2 courses 0.52 0.14–1.91
≥  3 courses 0.17 0.02–1.49
Respiratory distress 
syndrome
No 1 -
Yes 0.96 0.39–2.37
Ventilation No 1 - 1
1 week 2.15 0.2–22.58 2.3 0.23–23.35
1 – 2 weeks 3.45 0.30–39.91 4.57 0.40–51.63
> 2 weeks 8.27 0.86–79.74 9.02 0.96–85.0
Postnatal steroids No 1 - 1
Yes 2.69 1.05–6.89 2.91 1.17–7.28
Oxygen for 36 weeks No 1 -
Yes 1.29 0.59–2.87BMC Pediatrics 2005, 5:18 http://www.biomedcentral.com/1471-2431/5/18
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Association between gestational age, duration of ventilation and postnatal steroids administration Figure 2
Association between gestational age, duration of ventilation and postnatal steroids administration.
Association between gestational age, duration of ventilation, and severe ROP among VLBW infants stratified for administration  of postnatal steroids Figure 3
Association between gestational age, duration of ventilation, and severe ROP among VLBW infants stratified for administration 
of postnatal steroids.
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in accordance with our findings. The Cochrane meta-anal-
ysis reported an increased risk of 1.52 (95%CI 1.09–
2.12); we found an increased odds ratio of 2.91 (Table 2).
Regarding duration, the six studies in the Cochrane review
on late administration showed a wide variation in the
duration of the treatment (from 6 to 42 days) [17]. Dura-
tion and dose have not yet been addressed in a meta-anal-
ysis. Two observational studies have reported an effect of
duration and dose. Termote et al. reported that in VLBW
infants only prolonged use of postnatal hydrocortisone
was associated with an increased risk for severe ROP [29].
Haroon Parupia et al. suggested that a higher cumulative
dose of PNS was a risk factor for severe ROP, controlling
for other risk factors [30]. Consistent with these reports,
our findings have demonstrated that ≥  2 weeks duration,
which corresponds to a total of ≥  7 mg steroid dose, was
associated with an increased incidence of severe ROP (OR:
4.09, 95% CI: 1.52–11.03). This may be indicative that
only a longer duration of delayed PNS use is a risk factor
for severe ROP.
Limitations of our study were the long duration of the
period from 1993–2000 during which significant
advances have been made in the treatment protocol of
VLBW infants and could have influenced our results; how-
ever, we did not see any difference in the incidence of
severe ROP during the 1993 to 1996 and 1997 to 2000
periods (Figure 1). We believe that it was an advantage
that this observational study focused on a single tertiary
care center with little variability in practice. In particular,
the ophthalmologic examinations were consistent since
all neonates were seen by the same ophthalmologist for
the entire duration of the study. Another limitation is,
however, that we do not have information on the follow-
up of these infants after 6 months or after resolution of
the ROP. Also, at the beginning of our study, reports on
the effects of PNS on ROP were contradictory [13-16].
This study was initiated to explore predictive factors for
severe ROP, but not to test a priory hypotheses.
In our study we have included babies with birth weight <=
1500 g based on the joint statements of American Acad-
emy of Pediatrics and the American Academy of Ophthal-
mology guidelines for screening premature infants for
retinopathy of prematurity [31,32]. Our entry criteria dif-
fers from current practice, which is to screen neonates
with birth weights <= 1250 g or <= 28 weeks of gestation
based on the CRYO-ROP and LIGHT-ROP studies [33].
Our study also showed a substantial lower incidence of
severe ROP in infants >28 weeks of gestational age (Table
1)
In our explanatory model for ROP, after excluding non-
significant effects and non-confounding variables, the
incidence of severe ROP was associated only with three
factors (Table 2): gestational age, duration of ventilation,
and PNS treatment. These associations were intertwined
(Figures 2 and 3). Infants with lower gestational age were
more likely to have been ventilated for a longer duration,
received late PNS treatment for a longer period and devel-
oped severe ROP. We do not know whether late PNS treat-
ment is the risk factor or a marker of underlying illness
severity. A recent study reported short gestation, pro-
longed ventilation, frequent apnea and surfactant use as
risk factors for developing severe ROP, however, these fac-
tors again may be the marker for the severity of illness [8].
Regarding the pathogenesis of ROP, abnormal vascular
growth has been attributed to low insulin-like growth fac-
tor-1 (IGF-1) levels [34]. Genetic studies have shown that
IGF-1 is critical in vessel development [35], and IGF-1 lev-
els are correlated with birth weight and gestational age
[36-39]. The premature infants who develop ROP have
lower serum levels of IGF-1 than age-matched infants
without disease [40]. Low levels of IGF-1 have been sug-
gested to predict infants who will develop ROP and fur-
ther suggest that early restoration of IGF-1 in preterm
infants to normal levels could prevent this disease [34]. In
order to achieve a better understanding of the pathogene-
sis of ROP, future studies should investigate the role of
biologic markers. These studies can also determine the
impact of risk factors such as steroids (antenatal and post-
natal), gestational age, birthweight, oxygen administra-
tion, and duration of ventilation on biological markers
and specific mechanisms in the pathogenesis of ROP.
Conclusion
Prolonged use or higher cumulative dose of postnatal
hydrocortisone administered to treat chronic lung disease
after 3 weeks of life was associated with an increased rela-
tive risk for retinopathy of prematurity in very low birth
weight neonates.
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